A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.
Inclusion Criteria:
Participants must have at least one of the following characteristics:
Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drug (DMARD) (synthetic or biologic).
Exclusion Criteria:
Wyomissing, Pennsylvania 19610, United States
Svendborg, Region Syddanmark 5700, Denmark
Nantes, Loire-Atlantique 44093, France
Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54511, France
Frankfurt am Main, Hesse 60590, Germany
Hamburg, 20095, Germany
Budapest, Pest County 1027, Hungary
Budapest, Pest County 1033, Hungary
Ramat Gan, Central District 5262100, Israel
Poznan, Greater Poland Voivodeship 61-397, Poland
Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-168, Poland
Tomaszów Lubelski, Lublin Voivodeship 22-600, Poland
Ustroń, Silesian Voivodeship 43-450, Poland
Saint-Petersburg, Leningradskaya Oblast' 194291, Russia
Moscow, Moscow 115522, Russia
Moscow, Moscow Oblast 119991, Russia
Nizhny Novgorod, Nizhny Novgorod Oblast 603005, Russia
Saint Petersburg, Sankt-Peterburg 191015, Russia
Sant Joan Despí, Catalunya [Cataluña] 08970, Spain
Stanbul, Istanbul 34899, Turkey (Türkiye)
Istanbul, 34098, Turkey (Türkiye)
Newcastle upon Tyne, North Tyneside NE29 8NH, United Kingdom
London, Waltham Forest E11 1NR, United Kingdom